Ashland Reports Q3 2025 Results with Sales Decline

Ashland ( (ASH) ) just unveiled an update.

On July 29, 2025, Ashland Inc. reported its third-quarter fiscal 2025 results, revealing a 15% decline in sales to $463 million compared to the previous year, largely due to portfolio optimization initiatives. The company faced a net loss of $742 million, primarily due to a $706 million non-cash goodwill impairment charge. Despite these challenges, Ashland maintained strong margins through cost-saving measures and operational discipline, with Adjusted EBITDA aligning with expectations. The Life Sciences segment showed growth in pharma applications, while Personal Care experienced a decline due to portfolio changes and customer-specific softness. The company is optimistic about future growth due to strategic investments and market positioning.

The most recent analyst rating on (ASH) stock is a Hold with a $89.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.

Spark’s Take on ASH Stock

According to Spark, TipRanks’ AI Analyst, ASH is a Neutral.

Ashland’s overall stock score is weighed down by weak financial performance, negative valuation metrics, and mixed technical indicators. While there are pockets of strength in specific segments, such as Life Sciences and Personal Care, the company faces significant challenges with declining sales, profitability issues, and global market uncertainties.

To see Spark’s full report on ASH stock, click here.

More about Ashland

Ashland Inc. is a global additives and specialty ingredients company that holds leadership positions in high-quality, consumer-focused markets, including pharmaceuticals, personal care, and architectural coatings.

Average Trading Volume: 561,737

Technical Sentiment Signal: Sell

Current Market Cap: $2.33B

For a thorough assessment of ASH stock, go to TipRanks’ Stock Analysis page.